Quotient Sciences and Acesion Apply AI to Atrial Fibrillation Drugs
Quotient Sciences and Acesion Pharma announce a collaboration that will apply machine learning to formulation work for Acesion's atrial fibrillation drug pipeline, according to a press release.
Quotient Sciences will use its AI enhanced formulation service within the Translational Pharmaceutics platform. The service combines active machine learning with Bayesian optimization to analyze data, predict formulation performance and prioritize drug products for clinical testing.
The work will support oral formulation development for Acesion's early stage small molecule compounds. Acesion is developing SK ion channel inhibitors as potential treatments for atrial fibrillation.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Nov 22 SEIDOR launches a factory to build AI agents for SAP ERP Nov 21 Databricks in early talks to raise funds at about $225 billion valuation, WSJ reports Nov 21 AWS Quick adds chat-built flows, multi-agent answers and an updated web app Nov 21 Hitachi Digital launches HARC Compose to govern agentic engineering Nov 20 Auterion and SkyFall plan German factory to build drones for UkraineMore from Life Sciences
Nov 22 MedInTech raises $25.7 million for AI robotic endoscopes Nov 21 ModuleMD shows AI documentation, front-desk agents and skin-test measurement for allergy EHR Nov 21 Chelsea and Westminster Hospital launches multilingual AI avatar platform for lung cancer patients Nov 21 ChatGPT Health reaches Android, desktop and dots; health chats now follow the training setting Nov 20 OpenAI launches MedChemBench to test AI models on medicinal chemistry reasoningAI in Europe
Daily AI news from Europe, chosen by Rene van Pelt: European companies, the EU and the UK, chips and data centres, deals and regulation, in a few minutes.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
PharmaForceIQ Launches Share of Answer for Pharma AI Visibility
Lunit and Summit Test AI Pathology for Ivonescimab Research
AlphaLab launches Quanty One, an AI quant researcher
Atlas Bio raises $12.5 million for virtual drug trials
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Daily AI Brief: the AI news that matters, in your inbox.